Last reviewed · How we verify
Chlorhexidine 2%/Ethyl alcohol 7%
Chlorhexidine disrupts bacterial cell membranes and precipitates cytoplasmic contents, while ethyl alcohol denatures proteins and dissolves lipids, together providing rapid broad-spectrum antimicrobial activity.
Chlorhexidine disrupts bacterial cell membranes and precipitates cytoplasmic contents, while ethyl alcohol denatures proteins and dissolves lipids, together providing rapid broad-spectrum antimicrobial activity. Used for Skin antisepsis and disinfection prior to surgical procedures, Wound cleansing and antisepsis.
At a glance
| Generic name | Chlorhexidine 2%/Ethyl alcohol 7% |
|---|---|
| Sponsor | Hospital Regional de Alta Especialidad del Bajio |
| Drug class | Topical antiseptic combination |
| Modality | Small molecule |
| Therapeutic area | Infection prevention / Dermatology |
| Phase | Phase 3 |
Mechanism of action
Chlorhexidine is a biguanide antiseptic that binds to negatively charged bacterial cell membranes, causing leakage of intracellular components and cell death. Ethyl alcohol acts synergistically by denaturing bacterial proteins and disrupting lipid bilayers. This combination formulation is used as a topical antiseptic for skin preparation and disinfection.
Approved indications
- Skin antisepsis and disinfection prior to surgical procedures
- Wound cleansing and antisepsis
Common side effects
- Skin irritation or erythema
- Contact dermatitis
- Allergic reaction
Key clinical trials
- Physical Activity and Insulin Sensitivity Dynamics (NA)
- Systemic Amoxicillin Plus Metronidazole in Peri-implantitis Treatment (PHASE4)
- Comparison of Two Preoperative Antiseptic Solutions Alcohol Based in Abdominal Elective Surgeries (PHASE4)
- Metabolic Adaptation to High-frequent Hypoglycaemia in Type 1 Diabetes (NA)
- TEmporary Spinal CoRd StiMulatIon to PrevenNt Atrial FibrillaTION AFter Cardiac Surgery (NA)
- Mouthwash With Chlorhexidine 0.12%/Ethyl Alcohol 7% Compared to Ethyl Alcohol 7% (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: